No disclosed relationships extracted for NRXPyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Nothing on the wire mentions NRXP yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How NRXP has moved on past release days vs its typical ±4.6% day, and how often it closed up. Computed from daily closes — not a forecast.